{
    "id": 26430,
    "fullName": "PTEN R173S",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PTEN R173S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R173S has been identified in the scientific literature (PMID: 23434733), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Feb 2020).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 1066,
                    "pubMedId": 23434733,
                    "title": "Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23434733"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5728,
        "geneSymbol": "PTEN",
        "terms": [
            "PTEN",
            "10q23del",
            "BZS",
            "CWS1",
            "DEC",
            "GLM2",
            "MHAM",
            "MMAC1",
            "PTEN1",
            "PTENbeta",
            "TEP1"
        ]
    },
    "variant": "R173S",
    "createDate": "04/24/2017",
    "updateDate": "02/19/2020",
    "referenceTranscriptCoordinates": {
        "id": 169575,
        "transcript": "NM_000314",
        "gDna": "chr10:g.87952142C>A",
        "cDna": "c.517C>A",
        "protein": "p.R173S",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10644,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Refametinib (BAY 86-9766) demonstrated preliminary clinical activity in patients with several tumor types, including prolonged stable disease in an ocular melanoma patient harboring GNAQ Q209L and PTEN R173S (PMID: 23434733).",
            "molecularProfile": {
                "id": 27655,
                "profileName": "GNAQ Q209L PTEN R173S"
            },
            "therapy": {
                "id": 888,
                "therapyName": "Refametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1752,
                "name": "ocular melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1066,
                    "pubMedId": 23434733,
                    "title": "Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23434733"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27654,
            "profileName": "PTEN R173S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27655,
            "profileName": "GNAQ Q209L PTEN R173S",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 169575,
            "transcript": "NM_000314",
            "gDna": "chr10:g.87952142C>A",
            "cDna": "c.517C>A",
            "protein": "p.R173S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}